Related Experiment Videos
Psoriasis in association with prolactinoma: three cases.
M Sánchez Regaña1, P Umbert Millet
1Department of Dermatology, Hospital Sagrado Corazón, University of Barcelona, C/París 83-87 5th floor, 08029 Barcelona, Spain. ez.reg@teleline.es
The British Journal of Dermatology
|November 9, 2000
Summary
Psoriasis severity in three women worsened with prolactinoma development. Bromocriptine treatment, which lowers prolactin, improved their skin lesions, suggesting prolactin’s role in psoriasis.
Area of Science:
- Dermatology
- Endocrinology
- Immunology
Background:
- Plaque-type psoriasis is a chronic inflammatory skin condition.
- Prolactin is a hormone implicated in immune responses and cell proliferation.
Observation:
- Three women with plaque-type psoriasis developed prolactinoma.
- Increased psoriasis severity correlated with prolactinoma development.
Findings:
- Bromocriptine, a dopamine agonist suppressing prolactin, improved psoriasis symptoms in these patients.
- This suggests a potential link between prolactin levels and psoriasis activity.
Implications:
- Prolactin may play a role in the pathogenesis of psoriasis.
- Further research is warranted to explore the prolactin-psoriasis connection and potential therapeutic strategies.